Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A rare genetic disorder characterized by macular degeneration in the retina resulting in progressive loss of central vision with retention of the peripheral vision.
No HPO annotations are available for this condition.
Bestrophinopathies, the spectrum of ophthalmic disorders caused by pathogenic variants in BEST1, are typically characterized by retinal degeneration but may also be pan ophthalmic. The four recognized phenotypes are the three autosomal dominant disorders: Best vitelliform macular dystrophy (BVMD), BEST1 adult-onset vitelliform macular dystrophy (AVMD), and autosomal dominant vitreoretinochoroidopathy (ADVIRC); and autosomal recessive bestrophinopathy (ARB). Table 2. Bestrophinopathies: Frequency of Phenotypes
No consensus diagnostic criteria for bestrophinopathies have been published.
A bestrophinopathy should be suspected in individuals with following the ophthalmologic findings and electrophysiologic studies by phenotype, and family history. Ophthalmologic findings by phenotype
Source: GeneReviews — "Bestrophinopathies"
No approved treatments are currently available for vitelliform macular dystrophy. The disease remains an area of unmet medical need.
No clinical practice guidelines for bestrophinopathies have been published.
To establish the extent of disease and needs in an individual diagnosed with a bestrophinopathy, the evaluations summarized below (if not performed as part of the evaluation that led to the diagnosis) are recommended:
Ophthalmologic examination (including best-corrected visual acuity, visual fields, and SD-OCT) should be performed annually to monitor the progression of the fundus lesions and to evaluate for coincident development of choroidal neovascularization (CNV). In children, annual examinations are important in preventing the development of amblyopia, especially if there is a significant difference in the best-corrected visual acuity of one eye. A trial of conventional patching therapy of the better-seeing eye may be able to determine if amblyopia is present. Affected individuals should be advised to see their ophthalmologist in the event of decreased vision or metamorphopsia (straight lines appearing wavy), which could be signs of CNV. In some cases, affected individuals can be advised to use an Amsler grid for self-evaluation.
2 clinical trials registered, 2 recruiting. Interventions under study include other interventions and gene therapy. Pipeline includes 1 PHASE1. Research is sponsored by a mix of industry and academic institutions.
68 publications have been identified in PubMed for vitelliform macular dystrophy. Research spans Case Report / Case Series (26%), Basic Science / Preclinical (26%), and Epidemiology / Natural History (19%).
Research Type | Count | % of Total |
|---|---|---|
Patient case studies | 18 |
Data assembled from 4 of 12 sources · Last updated Sep 17, 2026, 10:07 PM UTC
Phenotype | Ophthalmologic Findings | Comment |
|---|---|---|
Most Common | Common | Infrequent |
BVMD | "Egg yolk"-like vitelliform lesion | Multiple vitelliform lesions; Atrophic scar |
Visual acuity can progress from 20/20 to 20/200. AVMD | Bilateral, small, circular vitelliform lesion | Atrophic scar |
Visual acuity 20/40 to 20/200 ADVIRC | Peripheral chorioretinal atrophy w/white retinal opacities | Hyperopia; Shallow anterior chamber/angle closure; Microcornea |
Fibrillar vitreous condensation | Breakdown of blood-retinal barrier w/retinal neovascularization | ARB |
Cystoid macular edema | Choroidal neovascularization | Subretinal deposits w/subretinal fluid in early stages progressing to subretinal fibrosis; Visual acuity can progress from 20/20 to 20/200. BVMD is a slowly progressive macular dystrophy typically with juvenile onset. |
Source: GeneReviews — "Bestrophinopathies"
Best vitelliform macular dystrophy (BVMD) is the second most common hereditary macular dystrophy. The most common heritable juvenile-onset macular dystrophy is Stargardt disease. Although the cause of adult-onset vitelliform macular dystrophy (AVMD) in most individuals is unknown, this phenotype is observed in the spectrum of bestrophinopathies and with heterozygous pathogenic variants in PRPH2 (encoding peripherin-2) (OMIM 179605), IMPG1 (OMIM 616151) and IMPG2 (OMIM 616152). Choroidal neovascularization is an acquired disorder.
Source: GeneReviews — "Bestrophinopathies"
Biomarker and diagnostic research for vitelliform macular dystrophy has been reported in the published literature.
Ophthalmologic examination, including best-corrected visual acuity, fundus examination, fundus photographs, and spectral-domain optical coherence tomography (SD-OCT) to determine the stage of disease
Consultation with a low vision specialist/clinic as needed
Consultation with a medical geneticist, certified genetic counselor, or certified advanced genetic nurse to inform affected individuals and their families about the nature, mode of inheritance, and implications of bestrophinopathies in order to facilitate medical and personal decision making
Low vision aids benefit those individuals with significantly reduced visual acuity. In the United States (US), educational issues for children with visual impairment can be addressed in the following:
Source: GeneReviews — "Bestrophinopathies"
Cessation of smoking helps prevent neovascularization of the retina .
Source: GeneReviews — "Bestrophinopathies"
Search ClinicalTrials.gov in the US and EU Clinical Trials Register in Europe for access to information on clinical studies for a wide range of diseases and conditions. Note: There may not be clinical trials for this disorder.
Source: GeneReviews — "Bestrophinopathies"
2 trials found
Source: GeneReviews — "Bestrophinopathies"
Laboratory research | 18 | 26% |
Disease patterns and progression | 13 | 19% |
Research summaries | 9 | 13% |
Testing and diagnosis research | 4 | 6% |
New treatment approaches | 3 | 4% |
Clinical study results | 2 | 3% |
Other research | 1 | 1% |
Ni RL (2026). [PMID: 41991505](https://pubmed.ncbi.nlm.nih.gov/41991505/). *Ophthalmic Genet*. [Basic Science / Preclinical]
Lewis TR (2026). [PMID: 41642651](https://pubmed.ncbi.nlm.nih.gov/41642651/). *The Journal of clinical investigation*. [Basic Science / Preclinical]
Tripathy K (2026). [PMID: 30725975](https://pubmed.ncbi.nlm.nih.gov/30725975/). *Unknown Journal*. [Other]
Sæther E (2026). [PMID: 41627933](https://pubmed.ncbi.nlm.nih.gov/41627933/). *Acta ophthalmologica*. [Epidemiology / Natural History]
De-Pablo-Gómez-De-Liaño B (2026). [PMID: 41813572](https://pubmed.ncbi.nlm.nih.gov/41813572/). *Ophthalmic genetics*. [Case Report / Case Series]
Parodi MB (2026). [PMID: 41914891](https://pubmed.ncbi.nlm.nih.gov/41914891/). *Retina*. [Diagnostic / Biomarker]
Padhy SK (2026). [PMID: 41795754](https://pubmed.ncbi.nlm.nih.gov/41795754/). *Documenta ophthalmologica. Advances in ophthalmology*. [Review / Meta-Analysis]
Feo A (2026). [PMID: 41198979](https://pubmed.ncbi.nlm.nih.gov/41198979/). *Eye (London, England)*. [Epidemiology / Natural History]
Constable PA (2026). [PMID: 41986808](https://pubmed.ncbi.nlm.nih.gov/41986808/). *Doc Ophthalmol*. [Review / Meta-Analysis]
Shmueli O (2026). [PMID: 41182355](https://pubmed.ncbi.nlm.nih.gov/41182355/). *Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie*. [Basic Science / Preclinical]